Johnson & Johnson (1JNJ)
Summary
1JNJ Chart
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusing on premium cardiovascular and vision franchises) should enhance margins and long-term growth prospects. TREMFYA's rapid adoption in IBD and the anticipated 2026 launch of icotrokinra position JNJ for continued immunology growth despite STELARA's LOE.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson (1JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Media Industry | Communication Services Sector | Joaquin Duato CEO | XMIL Exchange | US4781601046 ISIN |
| US Country | 138,100 Employees | 25 Nov 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
